- TRADE NAME: Vitrakvi (Loxo Oncology Inc)
- INDICATIONS: indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
- CLASS: Kinase inhibitor, Tropomyosin receptor kinase inhibitor
- HALF-LIFE: 2.9 hours
- FDA APPROVAL DATE: 11/26/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: can cause embryo-fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 09/29/2023
